NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia’s MammaPrint Now Included in First Coast Coverage for Medicare Breast Cancer Patients in Florida, Puerto Rico and the Virgin Islands
IRVINE, CA and AMSTERDAM – 2 May 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that First Coast Service Options Inc. (“First Coast”), the Medicare contractor for Read More
Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman
IRVINE, CA and AMSTERDAM – 12 April 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Read More
European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint Test with Highest Level 1A Clinical Evidence
MammaPrint® is the first and only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT trial IRVINE, CA and AMSTERDAM, 21 March 2017 – Agendia, a world leader in Read More







